Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms

Abstract

Context.-Malignant mesothelioma (MM) is a component of the BAP1 tumor predisposition syndrome. Other than in BAP1 familial studies, nonmesothelial neoplasms in individuals with MM has not been comprehensively assessed.Objective.-To assess the spectrum and prevalence of nonmesothelial neoplasms in individuals with MM.Design.-Individuals with MM and second neoplasms were identified from a database of 3900 MM cases. The expected prevalence of each type of neoplasm was calculated and compared with the actual prevalence in the study population using available Surveillance, Epidemiology, and End Results data and other published data.Results.-Two hundred seventy nonmesothelial neoplasms were identified in 241 individuals (6% of the study population) with MM. Prostate adenocarcinoma was most common. Non-Hodgkin lymphoma, Hodgkin lymphoma, lung carcinoma, urothelial carcinoma, breast carcinoma, chronic lymphocytic leukemia, clear cell renal cell carcinoma, head and neck squamous cell carcinoma, papillary renal cell carcinoma, multiple myeloma/plasmacytoma, meningioma, pleomorphic undifferentiated sarcoma, chronic myelogenous leukemia, ocular melanoma, hepatocellular carcinoma, liposarcoma, and Wilms tumor all were more prevalent than expected.Conclusions.-Nonmesothelial neoplasms are uncommon in individuals with MM, but certain tumor types are increased in prevalence. In an unselected study population with respect to BAP1 status, the prevalence of several tumor types described in BAP1 mutation carriers, including lung carcinoma, clear cell renal cell carcinoma, breast carcinoma, meningioma, pleomorphic undifferentiated sarcoma, and ocular melanoma, was increased.( Although the frequency of second neoplasms in individuals with MM has been examined in the context of familial studies of BAP1 mutation carriers, the prevalence and types of second neoplasms among individuals with MM unselected with regard to BAP1 status are unknown.1 The purpose of this study is to comprehensively assess the spectrum and prevalence of nonmesothelial neoplasms in individuals with MM. DESIGNThis study was approved by the institutional review board at Duke University Medical Center, Durham, North Carolina. A database of one of the authors consisting of 3900 MM cases received for professional and medicolegal consultation from 1982 through 2016 was searched retrospectively for individuals with MM who also had a history of one or more antecedent or synchronous (ie, diagnosed during same hospital admission) nonmesothelial neoplasms. The expected prevalence of each type of nonmesothelial neoplasm was calculated based on the overall estimated prevalence reported by the Surveillance, Epidemiology, and End Results (SEER) program for 2013 and US Census Bureau population data from the same year. 4 As SEER data do not separate renal cancers by histologic type, the expected prevalence for all renal cancers was calculated and we extrapolated the expected prevalence of clear cell renal cell carcinoma and papillary renal cell carcinoma to be less than that of a...

The Genomics of Liposarcoma: A Review and Commentary

“…Out of 4,432 unique liposarcoma records in SEER (1973-2015 cohort), 2968 (0.00063%) had a recording of other concurrent cancers. Liposarcoma have concurrent diagnoses in ovarian cancer 39 , hereditary nonpolyposis colorectal cancer 40 , Muire-Torre syndrome 41 , multiple myeloma 42 and CLL (also our recent unpublished data and infiltration in TCGA-SARC sample) 8 . Identifying these predisposition genes will enable us to interpret mutations in sporadic cases, as illustrated by the discovery of the telomere protection gene, POT1, as predisposing to angiosarcoma and cardiac sarcomas 39 .…”

Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study

“…[26][27][28][29] The full spectrum of this syndrome is still being characterised through the discovery of new associated tumours, including cutaneous squamous cell carcinoma, 30 basal cell carcinoma, 31,32 lung adenocarcinoma, 33 oesophageal adenocarcinoma, 34 breast cancer, 35 rhabdoid meningioma, 36 neuroendocrine tumours, 37 and certain types of sarcoma. 38,39 Some types of cancer associated with this syndrome may also have a poor prognosis. In the present study, significant associations of TC were identified with a cancer family history of cancers related to the BAP1 tumour predisposition syndrome, including mesothelioma, melanoma, squamous cell carcinomas, adenocarcinomas, sarcomas and breast cancer.…”

Bap1 Germline Mutation With Iridociliochoroidal Melanoma and Malignant Peritoneal Mesothelioma

“…Reprint requests: Arman Mashayekhi, MD, Ocular Oncology Service, 840 Walnut Street, Suite 1440, Philadelphia, PA 19107; e-mail: arman@shields.md patients, higher than the expected prevalence of 0.65% which was based on the overall estimated prevalence reported by the Surveillance, Epidemiology, and End Results (SEER) program for 2013 and U.S. Census Bureau population data from the same year. 6 In the general population, 80% of malignant pleural mesotheliomas occur in patients with a history of asbestos exposure, while the risk factors for malignant peritoneal mesothelioma are still not well established. 5 Interestingly, however, while only 20 to 30% of malignant pleural mesotheliomas were found to harbor BAP1 alterations, nearly 85% of malignant peritoneal mesotheliomas are associated with BAP1 mutation.…”

“…Choroidal melanoma and peritoneal mesothelioma are two rare cancers that can occur together in the setting of BAP1-TPDS. This novel hereditary cancer syndrome is characterized by autosomal dominant germline mutations in the BAP1 gene 1,6 and an increased risk of developing several benign and malignant tumors, including (in descending order of likelihood), choroidal melanoma, malignant mesothelioma, cutaneous melanoma, clear cell renal cell carcinoma, basal cell carcinoma, and atypical cutaneous Spitz tumor (melanocytic BAP-1 mutated atypical intradermal tumor, MBAIT). 1 Other related tumors include breast cancer, prostate cancer, cholangiocarcinoma, meningioma, neuroendocrine tumors, nonsmall cell lung adenocarcinoma, and thyroid cancer.…”